VNRX VolitionRX Limited gains 20% Jan 30, 2018

VolitionRx Limited, a life sciences company, focuses on developing blood-based tests to diagnose a range of cancers. The company is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants. The company also develops blood assays in the Nu.Q-M family to detect nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; blood assays in the Nu.Q-A family to detect nucleosome-protein adducts; and a Nu.Q-T assay to detect cancer by detecting total blood nucleosome levels. In addition, it develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to decide appropriate therapy; NuQ tests for non-cancer conditions; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore. http://www.priceseries.com/trade/VNRX-VolitionRX-Limited-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2018011620180130.html